BioCentury | Sep 29, 2020
Distillery Therapeutics

Blocking glucocorticoid signaling to increase checkpoint inhibitor sensitivity

...DISEASE CATEGORY: CancerINDICATION: Melanoma; colorectal cancerInhibiting the glucocorticoid receptor could...
...translational studies in multiple, undisclosed cancer types.TARGET/MARKER/PATHWAY: Glucocorticoid receptor (GCCR...
...and Harvard Harvard Medical School Brigham and Women's Hospital Glucocorticoid receptor (GCCR) Interleukin-27(IL-27...
BioCentury | Apr 24, 2020
Finance

Big gain for ORIC in trading debut after pricing upsized IPO

...raised $75 million at a valuation of $394.4 million. ORIC’s lead program, ORIC-101, is a GCCR...
...Seragon Pharmaceuticals, each of which was acquired by a large pharma, ORIC’s team has implicated GCCR...
...an exercise price of $11.50 per whole share. Targets CD73 (NT5E) - Ecto-5’-nucleotidase GCCR - Glucocorticoid receptor Paul...
BioCentury | Apr 22, 2020
Finance

April 21 Financial Quick Takes: ORIC’s IPO plans; plus venture rounds for Magpie, Cloudbreak, ReAlta, New Horizon, Zikani

...$75 million and value ORIC at $394.4 million. The company’s lead program, ORIC-101, is a GCCR...
BioCentury | Oct 31, 2019

GCCR inhibition could treat Ewing sarcoma

...the Weizmann Institute showed that GCCR inhibitors could be repurposed to treat Ewing sarcoma. The GCCR...
...in mice with metastatic Ewing sarcoma. Laboratoires Exelgyn markets Mifegyne for Cushing syndrome. TARGET/MARKER/PATHWAY: Glucocorticoid receptor (GCCR...
...CONTACT: Yosef Yarden, Weizmann Institute of Science, Rehovot, Israel email: yosef.yarden@weizmann.ac.il Claire Quang Weizmann Institute of Science Glucocorticoid receptor (GCCR...
BioCentury | Aug 9, 2019
Financial News

ORIC raises $55M to fund trials in drug-resistant cancers

...years of runway. ORIC's lead compound is based on research from Sawyers' lab, which implicated GCCR...
...series D will support a new Phase Ib trial slated for 3Q19 to evaluate the GCCR...
...an IPO was in the company’s near-term plans. Targets: CD73 (NT5E) - Ecto-5’-nucleotidase; GCCR - Glucocorticoid receptor Elizabeth...
BioCentury | Apr 2, 2019
Distillery Therapeutics

New glucocorticoid to treat steroid-resistant asthma

...DISEASE CATEGORY: Inflammation INDICATION: Asthma In vitro and mouse studies identified a glucocorticoid ligand of GCCR...
...preclinical PK/PD, toxicity and safety studies. GlaxoSmithKline plc markets Arnuity Ellipta for asthma. TARGET/MARKER/PATHWAY: Glucocorticoid receptor (GCCR...
...Rapids, Mich. email: eric.xu@vai.org Claire Quang Chinese Academy of Sciences Cleveland Clinic Foundation Harbin Institute of Technology Van Andel Institute Glucocorticoid receptor (GCCR) Asthma...
BioCentury | Nov 9, 2018
Clinical News

Clearside discontinues combo therapy for retinal vein occlusion

...Clearside Biomedical Inc. (NASDAQ:CLSD), Alpharetta, Ga. Product: Xipere (formerly CLS-TA) Business: Ophthalmic Molecular target: Glucocorticoid receptor (GCCR...
...at six months Status: Development discontinued Milestone: NA Brian Moy Zuprata (CLS-1001, CLS-TA, CLS 1001) Clearside Biomedical Inc. Glucocorticoid receptor (GCCR) Xipere...
BioCentury | Oct 4, 2018
Distillery Techniques

Assays and screens; biomarkers

...method identified correlations between high RNA expression and promoter accessibility for 130 genes, including the glucocorticoid receptor...
BioCentury | Sep 28, 2018
Financial News

Perceptive leads Lyra's $29.5M series B

...sinonasal tissue. LYR-210 is a long-acting formulation of mometasone furoate, an approved steroid targeting glucocorticoid receptor (GCCR...
BioCentury | Sep 26, 2018
Financial News

Perceptive leads Lyra’s $29.5M series B

...sinonasal tissue. LYR-210 is a long-acting formulation of mometasone furoate, an approved steroid targeting glucocorticoid receptor (GCCR...
Items per page:
1 - 10 of 157